A phase II clinical trial of ganetespib (STA-9090) in previously treated patients with advanced esophagogastric cancers

被引：0
|
作者：
Kwak, Eunice Lee
Goyal, Lipika
Abrams, Thomas Adam
Carpenter, Amanda
Wolpin, Brian M.
Wadlow, Raymond Couric
Allen, Jill N.
Heist, Rebecca Suk
McCleary, Nadine Jackson
Chan, Jennifer A.
Goessling, Wolfram
Schrag, Deborah
Evans, Colleen
Ng, Kimmie
Enzinger, Peter C.
Ryan, David P.
机构：
[1] Massachusetts Gen Hosp Canc Ctr, Div Hematol & Oncol, Boston, MA USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[5] Virginia Canc Specialists, Fairfax, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4090
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma
    Goyal, Lipika
    Wadlow, Raymond C.
    Blaszkowsky, Lawrence S.
    Wolpin, Brian M.
    Abrams, Thomas A.
    McCleary, Nadine Jackson
    Sheehan, Susan
    Sundaram, Eamala
    Karol, Michael D.
    Chen, John
    Zhu, Andrew X.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) : 128 - 137
  • [2] A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma
    Lipika Goyal
    Raymond C. Wadlow
    Lawrence S. Blaszkowsky
    Brian M. Wolpin
    Thomas A. Abrams
    Nadine Jackson McCleary
    Susan Sheehan
    Eamala Sundaram
    Michael D. Karol
    John Chen
    Andrew X. Zhu
    Investigational New Drugs, 2015, 33 : 128 - 137
  • [3] A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers.
    Riely, Gregory J.
    Yu, Helena Alexandra
    Stephens, Dennis
    Pietanza, Maria Catherine
    Smith-Marrone, Stephanie
    Fiore, John Joseph
    Goldstein, Melissa
    Sima, Camelia S.
    Kris, Mark G.
    Ginsberg, Michelle S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Hsp90 inhibitors in clinical development: STA-9090 (Ganetespib)
    Shapiro, G.
    ANNALS OF ONCOLOGY, 2011, 22 : 16 - 17
  • [5] Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
    Shah, Shalin
    Luke, Jason J.
    Jacene, Heather A.
    Chen, Tianqi
    Giobbie-Hurder, Anita
    Ibrahim, Nageatte
    Buchbinder, Elizabeth L.
    McDermott, David F.
    Flaherty, Keith T.
    Sullivan, Ryan J.
    Lawrence, Donald P.
    Ott, Patrick A.
    Hodi, F. Stephen
    MELANOMA RESEARCH, 2018, 28 (06) : 605 - 610
  • [6] AN OPEN-LABEL PHASE II STUDY OF THE HSP90 INHIBITOR GANETESPIB (STA-9090) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Socinski, Mark A.
    Koczywas, Marianna
    Goldman, Jonathan
    Paschold, Eugene
    Horn, Leora
    Lufkin, Joelle
    Blackman, Ronald K.
    Teofilovici, Florentina
    Shapiro, Geoffrey
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S467 - S468
  • [7] An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.
    Demetri, G. D.
    Heinrich, M. C.
    Chmielowski, B.
    Morgan, J. A.
    George, S.
    Bradley, R.
    Blackman, R. K.
    Teofilovici, F.
    Fletcher, J. A.
    Tap, W. D.
    von Mehren, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] A Phase I/II Trial of the Potent Hsp90 Inhibitor STA-9090 Administered Once Weekly In Patients with Advanced Hematologic Malignancies
    Lancet, Jeffrey E.
    Smith, B. Douglas
    Bradley, Robert
    Komrokji, Rami S.
    Teofilovici, Florentina
    Rizzieri, David A.
    BLOOD, 2010, 116 (21) : 1349 - 1350
  • [9] An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC)
    Wong, K.
    Koczywas, M.
    Goldman, J. W.
    Paschold, E. H.
    Horn, L.
    Lufkin, J. M.
    Blackman, R. K.
    Teofilovici, F.
    Shapiro, G.
    Socinski, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] A Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock Protein 90 Inhibitor, In Combination With Docetaxel in Subjects With Advanced Solid Tumour Malignancies
    Harvey, R. D.
    Lewis, C. M.
    Kauh, J. S.
    Owonikoko, T. K.
    Akintayo, A.
    Karol, M.
    Teofilovici, F.
    Lufkin, J. M.
    Khuri, F. R.
    Ramalingam, S. S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S153 - S153
12345